Evaluation of CREB gene expression to investigate resveratrol’s protective effect against sodium valproate-induced oxidative stress in mouse neural tissue
DOI:
https://doi.org/10.12923/cipms-2026-0011Keywords:
epilepsy, sodium valproate, resveratrol, oxidative stress, CREB geneAbstract
Sodium valproate (SV) is a widely used antiepileptic drug; however, its therapeutic application may be limited by its potential to induce oxidative stress. The present study evaluated the protective effect of resveratrol (REV) on CREB gene expression and malondialdehyde (MDA) levels in mouse neural tissue following prenatal exposure to sodium valproate. Fifteen Balb-C mice were kept in five groups of three per cage (two females and one male) and monitored daily for estrous cycles. After confirming pregnancy, the mice were divided into the following five groups: control, SV (400 mg/kg), SV (400 mg/kg) + REV (600 mg/kg), SV (400 mg/kg) + REV (350 mg/kg), and SV (400 mg/kg) + REV (225 mg/kg).
Drug interventions began on days eight to eighteen of pregnancy and continued until delivery. Two to three days before birth, eight fetuses from each group were surgically removed under anesthesia. Thebrain tissue was collected and CREB gene expression was measured using real-time PCR. Lipid peroxidation was assessed using the thiobarbituric acid reactive substances (TBARS) method to measure malondialdehyde (MDA) levels.
Sodium valproate significantly reduced CREB gene expression in brain tissue (p < 0.001) and increased MDA levels (p < 0.001). In contrast, resveratrol significantly upregulated CREB expression (p < 0.001) and reduced MDA concentrations, with the most pronounced gene expression effect observed at 350 mg/kg and the strongest reduction in lipid peroxidation at 600 mg/kg. The findings showed that resveratrol can effectively counteract sodium valproate-induced CREB gene downregulation and oxidative stress.
References
1. Stafstrom CE, Carmant L. Seizures and epilepsy: an overview for neuroscientists. Cold Spring Harb Perspect Med. 2015;5(6):a022426. doi: 10.1101/cshperspect.a022426.
2. Anwar H, Khan QU, Nadeem N, Pervaiz I, Ali M, Cheema FF. Epileptic seizures. Discoveries (Craiova). 2020;8(2):e110. doi: 10.15190/d.2020.7.
3. Ioannou P, Foster DL, Sander JW, Dupont S, Gil-Nagel A, Drogon O’Flaherty E, et al. The burden of epilepsy and unmet need in people with focal seizures. Brain Behav. 2022;12(9):e2589. doi: 10.1002/brb3.2589.
4. Balestrini S, Arzimanoglou A, Blümcke I, Scheffer IE, Wiebe S, Zelano J, et al. The aetiologies of epilepsy. Epileptic Disord. 2021;23(1):1-16. doi: 10.1684/epd.2021.1255.
5. Yang C, Liu Z, Wang Q, Wang Q, Liu Z, Luan G. Epilepsy as a dynamical disorder orchestrated by epileptogenic zone: a review. Nonlinear Dyn. 2021;104(3):1901-16. doi: 10.1007/s11071-021-06420-4.
6. Ghosh S, Sinha JK, Khan T, Devaraju KS, Singh P, Vaibhav K, et al. Pharmacological and therapeutic approaches in the treatment of epilepsy. Biomedicines. 2021;9(5):470. doi: 10.3390/biomedicines9050470.
7. Nevitt SJ, Marson AG, Weston J, Tudur Smith C. Sodium valproate versus phenytoin monotherapy for epilepsy: an individual participant data review. Cochrane Database Syst Rev. 2018;8(8):CD001769. doi: 10.1002/14651858.CD001769.pub4.
8. Contreras-García IJ, Cárdenas-Rodríguez N, Romo-Mancillas A, Bandala C, Zamudio SR, Gómez-Manzo S, et al. Levetiracetam mechanisms of action: from molecules to systems. Pharmaceuticals (Basel). 2022;15(4):475. doi: 10.3390/ph15040475.
9. Janković SM, Janković SV. Lessons learned from the discovery of sodium valproate and what has this meant to future drug discovery efforts? Expert Opin Drug Discov. 2020;15(11):1355-64. doi: 10.1080/17460441.2020.1795125.
10. Steele JW, Lin YL, Chen N, Wlodarczyk BJ, Chen Q, Attarwala N, et al. Embryonic hypotaurine levels contribute to strain-dependent susceptibility in mouse models of valproate-induced neural tube defects. Front Cell Dev Biol. 2022;10:832492. doi: 10.3389/fcell.2022.832492.
11. Reynolds EH, Green R. Valproate and folate: congenital and developmental risks. Epilepsy Behav. 2020;108:107068. doi: 10.1016/j.yebeh.2020.107068.
12. Singh D, Gupta S, Verma I, Morsy MA, Nair AB, Ahmed AF. Hidden pharmacological activities of valproic acid: a new insight. Biomed Pharmacother. 2021;142:112021. doi: 10.1016/j.biopha.2021.112021.
13. Ikeda Y, Tajika Y, Nagasaki Y. Design of self-assembling anti-epileptic drug for long-acting drug delivery in vivo. Biomater Sci. 2022;10(21):6307-14. doi: 10.1039/d2bm01064j.
14. Feng Y, Wei ZH, Liu C, Li GY, Qiao XZ, Gan YJ, et al. Genetic variations in GABA metabolism and epilepsy. Seizure. 2022;101:22-9. doi: 10.1016/j.seizure.2022.07.007.
15. Li D, Bai X, Jiang Y, Cheng Y. Butyrate alleviates PTZ-induced mitochondrial dysfunction, oxidative stress and neuron apoptosis in mice via Keap1/Nrf2/HO-1 pathway. Brain Res Bull. 2021;168:25-35. doi: 10.1016/j.brainresbull.2020.12.009.
16. Taleb A, Lin W, Xu X, Zhang G, Zhou QG, Naveed M, et al. Emerging mechanisms of valproic acid-induced neurotoxic events in autism and its implications for pharmacological treatment. Biomed Pharmacother. 2021;137:111322. doi: 10.1016/j.biopha.2021.111322.
17. Adewole KE, Attah AF, Osawe SO. Exploring phytotherapeutic approach in the management of valproic acid-induced toxicity. Adv Tradit Med. 2023;23(2):347-67. doi: 10.1007/s13596-021-00575-6.
18. Karimian M, Ghadiri M, Poormoosavi SM, Najafzadehvarzi H. Protective effects of resveratrol on the expression of catalase, glutathione peroxidase, and superoxide dismutase genes in the ovary and their activity in the serum of rats exposed to lead acetate: an experimental study. Int J Reprod Biomed. 2024;22(11):883-94. doi: 10.18502/ijrm.v22i11.17821.
19. Ashafaq M, Alam MI, Khan A, Islam F, Khuwaja G, et al. Nanoparticles of resveratrol attenuate oxidative stress and inflammation after ischemic stroke in rats. Int Immunopharmacol. 2021;94:107494. doi: 10.1016/j.intimp.2021.107494.
20. Ghafouri-Fard S, Bahroudi Z, Shoorei H, Hussen BM, Talebi SF, et al. Disease-associated regulation of gene expression by resveratrol: special focus on the PI3K/AKT signaling pathway. Cancer Cell Int. 2022;22(1):298. doi: 10.1186/s12935-022-02719-3.
21. Kim N, Park C, Jeong Y, Song MR. Functional diversification of motor neuron-specific Isl1 enhancers during evolution. PLoS Genet. 2015;11(10):e1005560. doi: 10.1371/journal.pgen.1005560.
22. Hamza AA, El Hodairy F, Badawi A. Safranal ameliorates sodium valproate-induced liver toxicity in rats by targeting gene expression, oxidative stress and apoptosis. J Biomed Pharm Res. 2015;4(6):46-60.
23. Siddiqui MA, Nazmi AS, Razia K, Karim S, Pal SN, Pillai KK. Oxidative damage in mice liver induced by sodium valproate: protection by melatonin. Indian J Pharmacol. 1999;31(6):427-30.
24. Hamza RZ, El-Shenawy NS. The beneficial effects of l-cysteine on brain antioxidants of rats affected by sodium valproate. Hum Exp Toxicol. 2017;36(11):1212-21. doi: 10.1177/0960327117695634.
25. Zohny SM, Habib MZ, Mohamad MI, Elayat WM, et al. Memantine/aripiprazole combination alleviates cognitive dysfunction in valproic acid rat model of autism: hippocampal CREB/BDNF signaling and glutamate homeostasis. Neurotherapeutics. 2023;20(2):464-83. doi: 10.1007/s13311-023-01360-w.
26. Walton MR, Dragunow I. Is CREB a key to neuronal survival? Trends Neurosci. 2000;23(2):48-53. doi: 10.1016/s0166-2236(99)01500-3.
27. Ziady AG, Sokolow A, Shank S, Corey D, et al. Interaction with CREB binding protein modulates the activities of Nrf2 and NF-κB in cystic fibrosis airway epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2012;302(11):L1221-31. doi: 10.1152/ajplung.00156.2011.
28. Naqvi S, Martin KJ, Arthur JS. CREB phosphorylation at Ser133 regulates transcription via distinct mechanisms downstream of cAMP and MAPK signalling. Biochem J. 2014;458(3):469-79. doi: 10.1042/BJ20131115.
29. Beltrán-Sarmiento E, Arregoitia-Sarabia CK, Floriano-Sánchez E, et al. Effects of valproate monotherapy on the oxidant-antioxidant status in Mexican epileptic children: a longitudinal study. Oxid Med Cell Longev. 2018;2018:7954371. doi: 10.1155/2018/7954371.
30. Rouaux C, Panteleeva I, René F, et al. Sodium valproate exerts neuroprotective effects in vivo through CREB-binding protein-dependent mechanisms but does not improve survival in an amyotrophic lateral sclerosis mouse model. J Neurosci. 2007;27(21):5535-45. doi: 10.1523/JNEUROSCI.1139-07.2007.
31. Mutlu E, Gibbs ST, South N, Pierfelice J, et al. Comparative toxicokinetics of trans-resveratrol and its major metabolites in Harlan Sprague Dawley rats and B6C3F1/N mice following oral and intravenous administration. Toxicol Appl Pharmacol. 2020;394:114962. doi: 10.1016/j.taap.2020.114962.
32. Chupradit S, Bokov D, Zamanian MY, et al. Hepatoprotective and therapeutic effects of resveratrol: a focus on anti-inflammatory and antioxidative activities. Fundam Clin Pharmacol. 2022;36(3):468-85. doi: 10.1111/fcp.12746.
33. Bai Y, Ma C, Jing X, et al. Resveratrol alleviates blast lung injury by modulating the epithelial sodium channel (ENaC) via the PI3K/AKT pathway. Int Immunopharmacol. 2025;147:113995. doi: 10.1016/j.intimp.2024.113995.
34. Kung HC, Lin KJ, Kung CT, Lin TK. Oxidative stress, mitochondrial dysfunction, and neuroprotection of polyphenols with respect to resveratrol in Parkinson’s disease. Biomedicines. 2021;9(8):918. doi: 10.3390/biomedicines9080918.
35. Iside C, Scafuro M, Nebbioso A, et al. SIRT1 activation by natural phytochemicals: an overview. Front Pharmacol. 2020;11:1225. doi: 10.3389/fphar.2020.01225.
36. Fakhri S, Iranpanah A, Gravandi MM, et al. Natural products attenuate PI3K/Akt/mTOR signaling pathway: a promising strategy in regulating neurodegeneration. Phytomedicine. 2021;91:153664. doi: 10.1016/j.phymed.2021.153664.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Zakieh Solbi, Gholamhassan Vaezi, Abbasali Dehpour, Nahid Masoudian, Vida Hojati (Autor)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
